Cv Rx, Inc. CVRX
Institutional shares held
14.4 Million
56.3K
calls
41.8K
puts
Total value of holdings
$224M
$873K
calls
$648K
puts
Market Cap
$319M
20,576,200
Shares Out.
Institutional ownership
70.2%
# of Institutions
86
We take great care to ensure that the data presented and summarized in this overview for CVRx, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding CVRX
View all-
Johnson & Johnson New Brunswick, NJ4.1MShares$63.7 Million11.52% of portfolio
-
Nea Management Company, LLC Timonium, MD2.37MShares$36.8 Million1.6% of portfolio
-
Black Rock Inc. New York, NY876KShares$13.6 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA824KShares$12.8 Million0.0% of portfolio
-
Parkman Healthcare Partners LLC Stamford, CT683KShares$10.6 Million0.85% of portfolio
-
Schonfeld Strategic Advisors LLC New York, NY545KShares$8.46 Million0.03% of portfolio
-
Balyasny Asset Management LLC Chicago, IL506KShares$7.86 Million0.01% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny435KShares$6.75 Million0.0% of portfolio
-
Emerald Advisers, LLC403KShares$6.26 Million0.15% of portfolio
-
Parian Global Management LP Pound Ridge, NY393KShares$6.1 Million11.93% of portfolio
Latest Institutional Activity in CVRX
Top Purchases
Top Sells
About CVRX
CVRx, Inc., a commercial-stage medical device company, focuses on developing, manufacturing, and commercializing neuromodulation solutions for patients with cardiovascular diseases. It offers Barostim, a neuromodulation device indicated to improve symptoms for patients with heart failure (HF) with reduced ejection fraction or systolic HF. The company sells its products through direct sales force, as well as sales agents and independent distributors in the United States, Germany, rest of Europe, and internationally. CVRx, Inc. was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.
Insider Transactions at CVRX
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Nov 21
2024
|
Paul Verrastro CHIEF MKTG & STRAT OFFICER |
SELL
Bona fide gift
|
Direct |
1,040
-55.47%
|
-
|
|
Nov 19
2024
|
Paul Verrastro CHIEF MKTG & STRAT OFFICER |
SELL
Open market or private sale
|
Direct |
1,430
-43.27%
|
$18,590
$13.58 P/Share
|
|
Nov 19
2024
|
Paul Verrastro CHIEF MKTG & STRAT OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
2,500
+43.07%
|
$12,500
$5.14 P/Share
|
|
Aug 15
2024
|
Joseph P Slattery |
BUY
Open market or private purchase
|
Direct |
3,000
+8.92%
|
$24,000
$8.1 P/Share
|
|
Aug 08
2024
|
Joseph P Slattery |
BUY
Open market or private purchase
|
Direct |
3,000
+9.79%
|
$24,000
$8.24 P/Share
|
|
Aug 06
2024
|
Joseph P Slattery |
BUY
Open market or private purchase
|
Direct |
2,500
+9.21%
|
$22,500
$9.09 P/Share
|
|
Aug 05
2024
|
Kevin Hykes PRES & CEO |
BUY
Open market or private purchase
|
Direct |
30,000
+50.0%
|
$240,000
$8.36 P/Share
|
|
Mar 25
2024
|
Craig E. Palmer SVP, U.S. SALES |
BUY
Exercise of conversion of derivative security
|
Direct |
934
+24.73%
|
$0
$0.24 P/Share
|
|
Feb 29
2024
|
Johnson & Johnson |
BUY
Exercise of conversion of derivative security
|
Indirect |
3,855
+0.01%
|
$0
$0.94 P/Share
|
|
Feb 23
2024
|
Paul Verrastro CHIEF MKTG & STRAT OFFICER |
SELL
Bona fide gift
|
Direct |
1,650
-67.21%
|
-
|
|
Feb 20
2024
|
Paul Verrastro CHIEF MKTG & STRAT OFFICER |
SELL
Open market or private sale
|
Direct |
2,545
-50.9%
|
$53,445
$21.91 P/Share
|
|
Feb 20
2024
|
Paul Verrastro CHIEF MKTG & STRAT OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
5,000
+50.0%
|
$25,000
$5.14 P/Share
|
|
Feb 16
2024
|
Johnson & Johnson |
SELL
Open market or private sale
|
Indirect |
3,725
-0.09%
|
$93,125
$25.81 P/Share
|
|
Feb 16
2024
|
Johnson & Johnson |
BUY
Exercise of in-the-money or at-the-money derivatives securities
|
Indirect |
607,725
+12.9%
|
$0
$0.16 P/Share
|
|
Jan 29
2024
|
Nadim Yared CHIEF EXECUTIVE OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
6,000
+10.6%
|
$0
$0.24 P/Share
|
|
Dec 28
2023
|
Joseph P Slattery |
BUY
Exercise of conversion of derivative security
|
Direct |
1,950
+2.14%
|
$1,950
$1.41 P/Share
|
|
Dec 14
2023
|
Ali Behbahani |
BUY
Exercise of conversion of derivative security
|
Direct |
316
+50.0%
|
$0
$0.24 P/Share
|
|
Oct 16
2023
|
Liz Galle VP OF GLOBAL CLINICAL RESEARCH |
BUY
Exercise of conversion of derivative security
|
Direct |
778
+50.0%
|
$0
$0.24 P/Share
|
|
Sep 18
2023
|
Jared Oasheim CHIEF FINANCIAL OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
5,862
+15.31%
|
$11,724
$2.1 P/Share
|
|
Sep 15
2023
|
Johnson & Johnson Innovation Jjdc, Inc. > 10% Shareholder |
SELL
Other acquisition or disposition
|
Direct |
3,495,575
-100.0%
|
-
|
Last 12 Months Summary
Buy / Acquisition
667K
Shares
From
9
Insiders
| Exercise of conversion of derivative security | 20.6K shares |
|---|---|
| Exercise of in-the-money or at-the-money derivatives securities | 608K shares |
| Open market or private purchase | 38.5K shares |
Sell / Disposition
10.4K
Shares
From
3
Insiders
| Open market or private sale | 7.7K shares |
|---|---|
| Bona fide gift | 2.69K shares |